COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents

  1. David H. Canaday
  2. Oladayo A. Oyebanji
  3. Elizabeth White
  4. Debbie Keresztesy
  5. Michael Payne
  6. Dennis Wilk
  7. Lenore Carias
  8. Htin Aung
  9. Kerri St. Denis
  10. Maegan L. Sheehan
  11. Sarah D. Berry
  12. Cheryl M. Cameron
  13. Mark J. Cameron
  14. Brigid M. Wilson
  15. Alejandro B. Balazs
  16. Christopher L. King
  17. Stefan Gravenstein

Reviewed by

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.ebiom.2022.104066
  2. ScreenIT

    SciScore for 10.1101/2021.12.07.21267179: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: Study approval was obtained from the WCG Institutional Review Board.
    Consent: All subjects or their legally authorized representatives provided informed consent.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    No key resources detected.

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Limitations of this study include the small sample size and the preponderance of males we recruited from a home for Veterans despite our efforts to resample all subjects in our prior cohort. We were unable to re-enroll subjects for a number of reasons, including refusal to obtain a booster vaccine, no longer working (HCWs) or living in the facility, and loss-to-follow-up due to non-COVID-19 interim mortality. We did not assess T-cell contribution to vaccine-induced immunity. Given the decline in antibody levels in the 6 months following initial vaccination1, and the substantial increase in anti-spike, RBD and neutralization levels after booster, our data strongly support current CDC recommendations for boosting NH residents and HCWs for the likelihood that it translates to increased clinical protection. Furthermore, there are now three reports in the general population of increased clinical protection after the booster shot providing further clinical support 8-10.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.12.07.21267179 on medRxiv